Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice

[1] Frohlich ED(1992)The heart in hypertension N Engl J Med 327 998-1008

[2] Apstein C(2002)Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995-1003

[3] Chobanian AV(2008)Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study Eur Heart J 29 741-7

[4] Devereux RB(2012)Heart disease and stroke statistics — 2012 update: a report from the American Heart Association Circulation 125 e2-e220

[5] Dustan HP(2003)Cardiac hypertrophy: the good, the bad, and the ugly Annu Rev Physiol 65 45-79

[6] Dzau V(2002)Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy JAMA 288 1491-8

[7] Dahlof B(2013)Targeting the renin-angiotensin-aldosterone system in heart failure Nat Rev Cardiol 10 125-34

[8] Devereux RB(2011)Rationale for combining a direct renin inhibitor with other renin-angiotensin system blockers. Focus on aliskiren and combinations Cardiovasc Drugs Ther 25 87-97

[9] Kjeldsen SE(2012)Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren Eur J Heart Failure 14 185-92

[10] Julius S(2012)The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis BMJ 344 e42-85

[1] Frohlich ED(1992)The heart in hypertension N Engl J Med 327 998-1008

[2] Apstein C(2002)Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995-1003

[3] Chobanian AV(2008)Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study Eur Heart J 29 741-7

[4] Devereux RB(2012)Heart disease and stroke statistics — 2012 update: a report from the American Heart Association Circulation 125 e2-e220

[5] Dustan HP(2003)Cardiac hypertrophy: the good, the bad, and the ugly Annu Rev Physiol 65 45-79

[6] Dzau V(2002)Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy JAMA 288 1491-8

[7] Dahlof B(2013)Targeting the renin-angiotensin-aldosterone system in heart failure Nat Rev Cardiol 10 125-34

[8] Devereux RB(2011)Rationale for combining a direct renin inhibitor with other renin-angiotensin system blockers. Focus on aliskiren and combinations Cardiovasc Drugs Ther 25 87-97

[9] Kjeldsen SE(2012)Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren Eur J Heart Failure 14 185-92

[10] Julius S(2012)The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis BMJ 344 e42-85